CYP3A Phenotyping

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Sanofi
SanofiPARIS, France
1 program
docetaxel + CEFN/A1 trial
Active Trials
NCT01110291Completed20Est. Mar 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Sanofidocetaxel + CEF

Clinical Trials (1)

Total enrollment: 20 patients across 1 trials

NCT01110291Sanofidocetaxel + CEF

Study of Usefulness of Genotyping to Predict Docetaxel Exposure and Adverse Events

Start: Apr 2003Est. completion: Mar 200920 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space